Marksans Pharma Q3 Surge: Revenue Jumps 10.6%, Profit Beats Expectations

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorRiya Kapoor|Published at:
Marksans Pharma Q3 Surge: Revenue Jumps 10.6%, Profit Beats Expectations
Overview

Marksans Pharma reported a robust Q3 FY26 with operating revenue climbing 10.6% YoY to ₹754.4 crore and EBITDA soaring 23.2% YoY to ₹160.7 crore, boosting the EBITDA margin by 217 bps to 21.3%. While nine-month PAT declined 7.1% YoY due to an early fiscal year slowdown and higher costs, the strong sequential improvement in Q3 highlights management's effective strategies. The company targets ₹3,000 crore revenue within a year, driven by global expansion and a focus on the OTC segment.

📉 The Financial Deep Dive

Marksans Pharma Limited has posted a strong third quarter for FY26, showcasing significant sequential recovery and robust year-on-year growth in key performance indicators. The company's operating revenue surged by 10.6% YoY to ₹754.4 crore in Q3 FY26, marking a healthy 4.7% increase QoQ. This top-line growth was complemented by a substantial 23.2% YoY jump in EBITDA, reaching ₹160.7 crore. Consequently, the EBITDA margin expanded by an impressive 217 basis points (bps) YoY to 21.3%, indicating improved operational efficiency and cost management.

Profit After Tax (PAT) for the quarter also saw a positive 8.2% YoY growth, settling at ₹113.7 crore. However, this quarterly resurgence contrasts with the performance for the first nine months (9M) of FY26. For the 9M period, revenue grew by 9.4% YoY to ₹2,094.8 crore, but EBITDA remained flat YoY at ₹405.4 crore, leading to a 184 bps YoY decline in the EBITDA margin to 19.4%. PAT for 9M FY26 fell by 7.1% YoY to ₹271.0 crore. Management attributed this to a softer first quarter, increased lease-related finance costs, and lower other income, while noting a significant profitability improvement in Q2 and Q3.

The company maintains a healthy balance sheet, reporting a ₹824.2 crore cash balance as of December 31, 2025. Cash flow from operations for 9MFY26 was robust at ₹263.2 crore, against a Capital Expenditure (CapEx) of ₹97.0 crore. Historically, Marksans Pharma has demonstrated strong profitability with ROE around 16-17% and ROCE around 20-21% (FY24/25), and a negative Net Debt to EBITDA ratio (indicating net cash surplus).

🚩 Risks & Outlook

Management expressed confidence in achieving sustainable growth, projecting a target of ₹3,000 crore in revenue within the next year. Key strategic drivers include expanding its global footprint through new subsidiaries in Europe and Canada to tap regulated markets, and a focused push into the burgeoning over-the-counter (OTC) segment, particularly in North America, with an aim to double revenue in the region. The company also seeks to become a top player in the UK market.

While the Q3 results signal a strong turnaround, potential risks include execution challenges in new market entries, currency fluctuations, and the competitive landscape in the pharmaceutical sector. The company's aggressive revenue targets imply a need for sustained operational excellence and market penetration. Investors will be watching the company's ability to convert its strategic initiatives into consistent profitability, especially given the flat EBITDA and declining PAT for the 9M period.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.